TRIM24 and dermatomyositis: In contrast, new cases of cancer were detected in anti-TIF1-Ab-negative cases throughout the 3–10 year period following DM onset, with 9.8% (95% CI 7.5, 12.0) at 5 years, 11.7% (95% CI 9.2, 14.2) at 7.5 years and 14.1% (95% CI 11.2, 16.8) at 10 years.